Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 16/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44567 | 1.00 | NLRP3 (0.43) | NLRP3ABCB1OPRM1OPRD1OPRK1 | |
| Taxine Ii SCHEMBL30563046 | 0.80 | — | — | |
| Taxinine A SCHEMBL30495377 | 0.80 | RAB9A (0.32) | ABCB1 | |
| SCHEMBL44737 | 0.72 | NLRP3 (0.47) | NLRP3ABCB1OPRM1OPRD1OPRK1 | |
| Taxuspine F SCHEMBL30602496 | 0.68 | RAB9A (0.31) | — | |
| SCHEMBL29394113 | 0.68 | ABCB1 (0.31) | ABCB1CYP2C19 | |
| SCHEMBL44183 | 0.67 | ABCB1 (0.41) | NLRP3ABCB1 | |
| SCHEMBL29425006 | 0.66 | NLRP3 (0.38) | NLRP3ABCB1CYP2C19 | |
| Taxagifine SCHEMBL29520283 | 0.66 | ABCB1 (0.40) | NLRP3ABCB1CYP2C19 | |
| Taxagifine SCHEMBL28964410 | 0.66 | ABCB1 (0.40) | NLRP3ABCB1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000924-A1 | Composition for the prevention, improvement or treatment of allergic disease comprising an extract of Taxus cuspidata as an active ingredient | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2025-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000924-A1 | Composition for the prevention, improvement or treatment of allergic disease comprising an extract of Taxus cuspidata as an active ingredient | SERPINB1, TSLP, CMA1 | NLRP3 1715/4885ABCB1 123/4885OPRM1 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.